Peptide library / Immune & defense / Brilacidin
Brilacidin
An experimental antibiotic mimic of host defence peptides.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Skin infectionsSmall human studies
- Oral mucositis, studiedSmall human studies
How it is thought to work
Brilacidin is a small non-peptide molecule that copies the structure of defensins and disrupts bacterial membranes.
What the evidence shows
A phase 2 trial in skin infections showed efficacy with a single dose. Interest has also centred on oral mucositis and inflammatory bowel disease.
Safety and unknowns
Limited safety data beyond early trials.
Regulatory status
Not approved. In early to mid-stage clinical development.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Colistin
FDA-approvedA last-resort polypeptide antibiotic for highly resistant Gram-negative infections.
Cyclosporine
FDA-approvedAn 11 amino acid cyclic peptide from a soil fungus that made organ transplantation routine.
Bacitracin
FDA-approvedA cyclic peptide antibiotic found in many over-the-counter wound ointments.
General information, not medical advice. Do not buy or inject unregulated peptides.